MedTrace Logo

Glucose Variability With DPP-4 Inhibition

NCT01751321 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-12-17

No results posted yet for this study

Summary

Glucose Variability With DPP-4 Inhibition

Conditions

Interventions

DRUG

Sitagliptin, placebo

sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day

Sponsors & Collaborators

  • Research Clinical Centre of the Russian Railways, JSC

    lead OTHER

Principal Investigators

  • Alexander Ametov, MD · Research Clinical Centre of the Russian Railways, JSC

Study Design

Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-09-30
Completion
2013-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01751321 on ClinicalTrials.gov